Document:

Exhibit 10.19

 

		Notice of Award	
	SMALL BUSINESS INNOVATION RESEARCH PROG         Issue Date:    04/23/2013
	Department of Health and Human Services

 National Institutes of Health
	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES 

 

Grant Number: 5R44AR058041-03

 

Principal Investigator(s):

LATHA PAKA, PHD

 

Project Title: Anti-Fibrotic Therapy for Scleroderma/SSc

 

Dr. Goldberg, Itzhak D, MD

Angion Biomedica Corp.

51 Charles Lindbergh Blvd

Uniondale, NY 115304888

 

Award e-mailed to: igoldberg@angion.com

 

Budget Period: 05/01/2013 – 04/30/2014

Project Period: 01/04/2010 – 04/30/2015

 

Dear Business Official:

 

The National Institutes of Health hereby awards a grant
in the amount of $619,112 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III)
to ANGION BIOMEDICA CORPORATION in support of the above referenced project. This award is pursuant to the authority of 42 USC 241
42 CFR PART 52 15 USC 638 and is subject to the requirements of this statute and regulation and of other referenced, incorporated
or attached terms and conditions.

 

Acceptance of this award including the “Terms and
Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document about
research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research
reported in this publication was supported by the National Institute Of Arthritis And Musculoskeletal And Skin Diseases of the
National Institutes of Health under Award Number R44AR058041. The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning
the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research
by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under
NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance
with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August
24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with
the 1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation
does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult
the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

If you have any questions about this award, please contact
the individual(s) referenced in Section IV.

 

Sincerely yours,

 

Gail Hamilton

Grants Management Officer

NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND
SKIN DISEASES

 

	1	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

  

Additional
information follows

  

	 	2	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

  

	 	SECTION I – AWARD DATA – 5R44AR058041-03

  

	Award Calculation (U.S. Dollars)	 	 	 
	 	 	 	 
	Federal Direct Costs	 	$	[***]	 
	Federal F&A Costs	 	$	[***]	 
	Approved Budget	 	$	[***]	 
	Fee	 	$	[***]	 
	Federal Share	 	$	[***]	 
	TOTAL FEDERAL AWARD AMOUNT	 	$	619,112	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION (FEDERAL SHARE)	 	$	619,112	 

 

	SUMMARY
    TOTALS FOR ALL YEARS
	YR	 	THIS
    AWARD	 	 	CUMULATIVE
    TOTALS	 
	3	 	$	619,112	 	 	$	619,112	 
	4	 	$	1,584,102	 	 	$	1,584,102	 

 

Recommended future year total cost support, subject
to the availability of funds and satisfactory progress of the project

 

	Fiscal Information:	 
	CFDA Number:	93.846
	EIN:	1113430072A1
	Document Number:	RAR058041B
	Fiscal Year:	2013

 

	IC	 	CAN	 	 	2013	 	 	2014	 
	AR	 	 	8472495	 	 	$	619,112	 	 	$	1,584,102	 

 

Recommended future year total cost support, subject
to the availability of funds and satisfactory progress of the project

  

NIH Administrative Data:

PCC: 1 F / OC: 414E / Released:
HAMILTONG 04/22/2013

Award Processed: 04/23/2013 12:09:43 AM

 

	 	SECTION II – PAYMENT/HOTLINE INFORMATION – 5R44AR058041-03

 

For payment and HHS Office of Inspector General Hotline
information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

	 	SECTION III – TERMS AND CONDITIONS – 5R44AR058041-03

 

This award is based on the application submitted to,
and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or
by reference in the following:

 

		a.	The grant program legislation and program regulation cited in this Notice of Award.

		b.	Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations
acts.

		c.	45 CFR Part 74 or 45 CFR Part 92 as applicable.

		d.	The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

		e.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

 

(See NIH Home Page at ‘http://grants.nih.gov/grants/policy/awardconditions.htm’
for certain references cited above.)

 

Carry over of an unobligated balance into the next budget
period requires Grants Management Officer prior approval.

 

	 	3	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

  

    	 

    	 

    

 

This award is subject to the requirements of 2 CFR Part
25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration
in the Central Contractor Registration. Should a consortium/subaward
be issued under this award, a DUNS requirement must be included. See  http://grants.nih.gov/grants/policy/awardconditions.htm
 for the full NIH award term implementing this requirement and other additional information.

 

This award is not subject to the Transparency Act subaward
and executive compensation reporting requirement of 2 CFR Part 170.

 

In accordance with P.L. 110-161, compliance with the
NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: 
http://publicaccess.nih.gov/.

 

Treatment of Program Income:

Additional Costs

 

	 	SECTION IV – AR Special Terms and Conditions – 5R44AR058041-03

 

NON-COMPETING FUNDING LEVEL UNDER A CONTINUING RESOLUTION
NIH is currently funded through a Continuing Resolution at the FY2012 level plus 0.6 percent (See NIH Guide Notice NOT-OD-13-002:
http://grants.nih.gov/grants/guide/notice-files/NOT-OD- 13-002.html. This non-competing award has been made at a level below that
committed for FY2013 in the previous Notice of Award. If the final appropriation permits, adjustments may be made up to the FY2013
funding plan level.

 

FINANCIAL REQUIREMENTS

This award is subject to the requirements pertaining
to the awardee?s financial and business management systems. Prior to drawing down funds for this award from the payment system,
the awardee is required to have in place written policies and procedures for financial and business management systems that comply
with NIH policy, and must follow those policies and procedures for the duration of this project.

 

INTELLECTUAL PROPERTY RIGHTS

Normally, the awardee organization retains the principal
worldwide patent rights to any invention developed with United States Government support. Under Title 37 Code of Federal Regulations
Part 401, the Government receives a royalty-free license for its use, reserves the right to require the patent holder to license
others in certain circumstances, and requires that anyone exclusively licensed to sell the invention in the United States must
normally manufacture it substantially in the United States.

 

Rights and obligations related to inventions created
or reduced to practice as a result of this award are detailed in 35 U.S.C. 205 and 37 CFR Part 401. These inventions must be reported
to the Extramural Invention Reporting and Technology Resources Branch, OPERA, NIH, 6701 Rockledge Drive, MSC 7750, Bethesda, MD
20892-7750, (301) 435-1986. For additional information, access the NIH link on the Interagency Edison web site (www.iedison.gov)
which includes an electronic invention reporting system, reference information and the text to 37 CFR 401.

 

To the extent authorized by 35 U.S.C., Section 205, the
Government will not make public any information disclosing an NIH-supported invention for a 4-year period to allow the awardee
organization a reasonable time to file a patent application, nor will the Government release any information that is part of that
patent application.

 

FEES

If a fee is provided as part of this Notice of Grant
Award it is in addition to direct and facilities and administrative costs. The fee is to be drawn down from the DHHS Payment Management
System, http://www.dpm.psc.gov/ in increments proportionate to the draw down of costs.

 

ALLOWABLE COSTS

Allowable costs conducted by for-profit organizations
will be determined by applying the cost

principles of Contracts with Commercial Organizations
set forth in 48 CFR, Subpart 31.2.

 

	 	4	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

  

    	 

    	 

    

  

PAYMENT MANAGEMENT SYSTEM

Advances of Federal funds must be maintained in a Federally
insured and interest bearing account. Questions concerning access to the Payment Management System (PMS) should be directed to
the PMS office at (877) 614-5533. The website is: http://www.dpm.psc.gov/

 

SALARY CAP

None of the funds in this award shall be used to pay
the salary of an individual at a rate in excess of the currently mandated NIH salary cap. Please refer to the NIH Guide for Grants,
Cooperative Agreements, and Contracts, Notice: OD-12-035, dated January 20, 2012.

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for the
negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions.
The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work
together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should
be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist: Yen Thach

Email: thachy@mail.nih.gov Phone: 301-594-3505
Fax: 301-480-5450

 

Program Official: Hung H Tseng

Email: tsengh@mail.nih.gov Phone: 301-496-0810
Fax: 301-480-4543

 

SPREADSHEET SUMMARY

GRANT NUMBER: 5R44AR058041-03

 

INSTITUTION: ANGION BIOMEDICA CORPORATION

 

	Facilities
    and Administrative Costs	 	Year
    3	 	 	Year
    4	 
	F&A Cost Rate 1	 	 	90	%	 	 	90	%
	F&A Cost Base 1	 	$	[***]		 	$	[***]	
	F&A Costs 1	 	$	[***]		 	$	[***]	

 

	 	5	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit 10.20

 

		Notice of Award	
	SMALL BUSINESS INNOVATION RESEARCH PROG           Issue Date:     08/01/2013
	Department of Health and Human Services 

National Institutes of Health
	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

 

Grant Number: 2R44DK085841-02A1 REVISED

 

Principal Investigator(s):

PRAKASH NARAYAN, PHD

 

Project Title: Antifibrotic Therapy for Chronic
Kidney Disease

 

Dr. Goldberg, Itzhak D, MD

Angion Biomedica Corp. 

1050 Stewart Ave

Garden City, NY 115304888

 

Award e-mailed to: igoldberg@angion.com

 

Budget Period: 08/01/2012 – 07/31/2013

Project Period: 08/01/2012 – 07/31/2014

 

Dear Business Official:

 

The National Institutes of Health hereby revises
this award to reflect an increase in the amount of $59,042 (see “Award Calculation” in Section I and “Terms
and Conditions” in Section III) to ANGION BIOMEDICA CORPORATION in support of the above referenced project. This award is
pursuant to the authority of 42 USC 241 15 USC 638 42 CFR 52 and is subject to the requirements of this statute and regulation
and of other referenced, incorporated or attached terms and conditions.

 

Acceptance of this award including the “Terms
and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document
about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research
reported in this publication was supported by the National Institute Of Diabetes And Digestive And Kidney Diseases of the National
Institutes of Health under Award Number R44DK085841. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome
of this research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research
by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under
NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with
42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24,
2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the
1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does
not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the
NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

If you have any questions about this award, please
contact the individual(s) referenced in Section IV.

 

Sincerely yours,

 

Pamela Love

Grants Management Officer

  

	1	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
KIDNEY DISEASES

 

Additional information follows

 

	 	2	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

	 	SECTION I – AWARD DATA – 2R44DK085841-02A1 REVISED

 

	Award Calculation (U.S. Dollars)	 	 	 
	Salaries and Wages	 	$	[***]	 
	Fringe Benefits	 	$	[***]	 
	Consultant Services	 	$	[***]	 
	Equipment	 	$	[***]	 
	Supplies	 	$	[***]	 
	Travel Costs	 	$	[***]	 
	 	 	 	 	 
	Federal Direct Costs	 	$	[***]	 
	Federal F&A Costs	 	$	[***]	 
	Approved Budget	 	$	[***]	 
	Fee	 	$	[***]	 
	Federal Share	 	$	[***]	 
	TOTAL FEDERAL AWARD AMOUNT	 	$	902,494	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION (FEDERAL SHARE)	 	$	[***]	 

 

	SUMMARY TOTALS FOR ALL YEARS	 
	YR	 	THIS AWARD	 	 	CUMULATIVE TOTALS	 
	2	 	$	902,494	 	 	$	902,494	 
	3	 	$	1,002,967	 	 	$	1,002,967	 

 

Recommended future year total cost support, subject
to the availability of funds and satisfactory progress of the project

 

	Fiscal Information:	 
	CFDA Number:	93.847
	EIN:	1113430072A1
	Document Number:	RDK085841B
	Fiscal Year:	2012

 

	IC	 	 	CAN	 	 	2012	 	 	2013	 
	DK	 	 	8469933	 	 	$	902,494	 	 	$	1,002,967	 

 

Recommended future year total cost support, subject
to the availability of funds and satisfactory progress of the project

 

NIH Administrative Data:

PCC: KMM KSB / OC: 414B / Released:
LOVEP 07/31/2013

Award Processed: 08/01/2013 12:14:13 AM

 

	 	SECTION II – PAYMENT/HOTLINE INFORMATION – 2R44DK085841-02A1 REVISED

 

For payment and HHS Office of Inspector General
Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

	 	SECTION III – TERMS AND CONDITIONS – 2R44DK085841-02A1 REVISED

 

This award is based on the application submitted
to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly
or by reference in the following:

 

		a.	The grant program legislation and program regulation cited in this Notice of Award.

		b.	Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations
acts.

		c.	45 CFR Part 74 or 45 CFR Part 92 as applicable.

		d.	The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the
budget period.

		e.	This award notice, INCLUDING THE TERMS AND CONDITIONS
CITED BELOW.

 

	 	3	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

  

(See NIH Home Page at ‘http://grants.nih.gov/grants/policy/awardconditions.htm’
for certain references cited above.)

 

An unobligated balance may be carried over into the
next budget period without Grants Management Officer prior approval.

 

This grant is subject to Streamlined Noncompeting
Award Procedures (SNAP).

 

This award is subject to the requirements of 2 CFR
Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration
in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included.
See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and
other additional information.

 

This award is not subject to the Transparency Act
subaward and executive compensation reporting requirement of 2 CFR Part 170.

 

In accordance with P.L. 110-161, compliance with
the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

 

Treatment of Program Income:

Additional Costs

 

	 	SECTION IV – DK Special Terms and Conditions – 2R44DK085841-02A1 REVISED

 

REVISION #2:

 

Revised award issued to restore the Small Business
Innovation Research (SBIR) fee rate of 7% of the total cost of the award in the amount of 59,042 for FY2012 and 65,615 for FY2013.

 

All other terms and conditions of the original award
also apply to this award.

 

REVISION #1 :

 

Revised award to change CAN number from 8425512 to
correct CAN number 8469933.

 

All other terms and conditions of the original award
also apply to this award.

 

This award is issued in accordance with the NIH 2012
fiscal policies described in the NIH Guide Notice NOT-OD-12-036: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-036.html

 

Prior to drawing down funds for this award from the
payment management system, you are required to have in place written policies and procedures for financial and business management
systems. Your systems must comply with the standards included in the attachment to the letter/email “Requirements for Financial
and Business Management Systems Requirements for SBIR/STTR Awardees” which was sent to your organization’s Business Official
on April 27, 2012. The policies and procedures must remain in effect for the duration of this project.

 

In addition to the PI, the following individuals
are named as key personnel:

 

(Dr Itzhak D. Goldberg)

 

Written prior approval is required if any of the
individual(s) named above withdraws from the project entirely, is absent from the project during any continuous period of 3 months
or more, or reduces time devoted to the project by 25 percent or
more from the level that was approved at the time of award.

 

	 	4  	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

This grant is in response to PA11-096. Acceptance
of this award requires compliance with this solicitation. See the NIH Guide at http://grants.nih.gov/grants/guide/index.html for
copy of the RFA/PA that includes administrative and programmatic requirements specific to this award.

 

Notice: Under governing regulations, Federal funds
administered by the Department of Health and Human Services shall not be expended for research involving human subjects, and individuals
shall not be enrolled in such research, without prior approval by the Office of Human Research Protections (OHRP) of an assurance
to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction applies to all collaborating
sites without OHRP- approved assurances, whether domestic or foreign, and compliance must be ensured by the awardee.

 

Notice: Under governing policy, Federal funds administered
by the National Institutes of Health (NIH) shall not be expended for research involving live vertebrate animals without prior approval
by the Office for Laboratory Animal Welfare (OLAW) of an assurance to comply with the NIH policy on humane care and use of laboratory
animals. This restriction applies to all performance sites (e.g., collaborating institutions, subcontractors, subgrantees) without
OLAW-approved assurances, whether domestic or foreign.

 

The fee provided as part of this grant award is in
addition to the allowable direct and indirect costs. An adjustment of the fee will be made in the event the grant is terminated.
The fee should be drawn down from the DHHS Division of Payment Management (DPM) in increments proportional to the draw down of
funds for costs. Questions concerning access to the DPM should be directed to the DPM office at(877)614-5533.

 

Allowable costs of activities
conducted by for-profit organizations will be determined by applying the cost principles of the Federal Acquisition Regulation
set forth in 48 CFR, Subpart 31.2. (see http://www.access.gpo.gov/nara/cfr/waisidx_01/48cfr31_01.html)

 

Intellectual property rights: Normally, the awardee
organization retains the principal worldwide patent rights to any invention developed with United States government support. Under
Title 37 Code of Federal Regulations Part 401, the government receives a royalty free license for its use, reserves the right to
require the patent holder to license others in certain circumstances, and requires that anyone exclusively licensed to sell the
invention in the United States must normally manufacture it substantially in the United States.

 

Rights and obligations related to inventions created
or reduced to practice as a result of this award are detailed in 35 U.S.C. 205 and 37 CFR Part 401. These inventions must be reported
to the Extramural Invention Reporting and Technology Resources Branch, OPERA, NIH, 6705 Rockledge Drive, MSC 7980, Bethesda, MD
20892-7980, (301) 435-1986. For additional information, access the NIH link on the interagency Edison web site (www.iedison.gov)
which includes an electronic invention reporting system, reference information and the text to 37 CFR 401.

 

To the extent authorized by 35 U.S.C., Section 205,
the government will not make public any information disclosing an NIH-supported invention for a 4-year period to allow the awardee
organization a reasonable time to file a patent application, nor will the government release any information that is part of that
patent application.

.

Prior approval to implement budgetary and programmatic
changes, where required by NIH Policy, (See the NIH Grants Policy Statement for prior approval requirements at: http://grants.nih.gov/grants/policy/nihgps_2010/nihgps_ch8.htm)
must be obtained in writing from the Grants Management contact shown on this Notice of Award. A letter signed by the Principal
Investigator and a Business Official of the Grantee Institution, and should include an explanation and justification for the action(s).
Requests may be made via e-mail provided they are routed through these same officials. If there are questions as to whether an
action requires prior approval, contact the Grants Management Specialist.

 

The grantee is required to establish a positive time
and effort reporting system.

 

Grantees must access a website to determine which
progress reports are due. The Office of Policy for Extramural Research Administration, OER, National Institutes of Health (NIH)
hosts the website located at: http://era.nih.gov/userreports/pr_due.cfm.
Grantees are responsible for periodically checking the list, which is updated on/around the 30th of each month. In addition to
this website, e-mail reminders are sent to the Principal Investigator.

 

	 	5	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

  

Effective October 1, 2004, NIH centralized receipt
and initial processing of all NIH non-competing progress reports. The new centralized mailing address for all NIH Institutes/Centers
(IC) is now:

 

Division of Extramural Activities Support, OER

National
Institutes of Health

6705 Rockledge Drive, Room 2207, MSC 7987

Bethesda, MD 20892-7987 (for regular or US Postal
Service Express mail)

Bethesda, MD 20817 (for other courier/express mail delivery only)

Phone Number: (301) 594-6584

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for
the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions.
The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work
together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should
be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist: Krystle Nicholson

Email: nicholsonk@niddk.nih.gov Phone:
301-594-8860 Fax: 301-480-3504

 

Program Official: Marva M. Moxey-mims

Email: moxey-mimsm@extra.niddk.nih.gov Phone:
(301) 451-5037 Fax: (301) 480-3510

 

SPREADSHEET SUMMARY

GRANT NUMBER: 2R44DK085841-02A1 REVISED

 

INSTITUTION: ANGION BIOMEDICA CORPORATION

 

	Budget	 	Year
    2	 	 	Year
    3	 
	Salaries and Wages	 	$	[***]	 	 	$	[***]	 
	Fringe Benefits	 	$	[***]	 	 	$	[***]	 
	Consultant Services	 	$	[***]	 	 	$	[***]	 
	Equipment	 	$	[***]	 	 	 	 	 
	Supplies	 	$	[***]	 	 	$	[***]	 
	Travel Costs	 	$	[***]	 	 	$	[***]	 
	FEE	 	$	[***]	 	 	$	[***]	 
	TOTAL FEDERAL DC	 	$	[***]	 	 	$	[***]	 
	TOTAL FEDERAL F&A	 	$	[***]	 	 	$	[***]	 
	TOTAL COST	 	$	902,494	 	 	$	1,002,967	 

 

	Facilities
    and Administrative Costs	 	Year
    2	 	 	Year
    3	 
	F&A Cost Rate 1	 	 	90	%	 	 	90	%
	F&A Cost Base 1	 	$	[***]	 	 	$	[***]	 
	F&A Costs 1	 	$	[***]	 	 	$	[***]	 

 

	 	6	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]